Five firms in Pakistan, India allowed to make and sell remdesivir

Published May 15, 2020
Remdesivir is the only drug approved to treat Covid-19 patients after promising early trial results. — AFP/File
Remdesivir is the only drug approved to treat Covid-19 patients after promising early trial results. — AFP/File

NEW DELHI: To expand the drug’s access, Gilead Sciences said this week it had signed non-exclusive licensing pacts with five generic drug-makers based in India and Pakistan, allowing them to make and sell remdesivir for 127 countries.

But health access groups claim the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drug-makers.

Remdesivir is the only drug approved to treat Covid-19 patients after promising early trial results prompted US regulators to grant emergency use authorisation on May 2.

Two health advocacy groups, meanwhile, have written to the Indian government asking it to rescind patents given to Gilead for remdesivir so it can be distributed more fairly to coronavirus patients around the world.

Drug patents in India are an important issue as many countries depend on generic drug-makers to make and sell cheaper versions of critical drugs to them. Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.

“The licences divide the global market into two and profitable markets are retained with Gilead and less profitable markets are given to the five generic companies,” said K. Gopakumar, senior legal researcher at Third World Network, which sent a letter to the Indian government on Wednesday.

Published in Dawn, May 15th, 2020

Follow Dawn Business on Twitter, LinkedIn, Instagram and Facebook for insights on business, finance and tech from Pakistan and across the world.

Opinion

Editorial

‘Source of terror’
Updated 29 Mar, 2024

‘Source of terror’

It is clear that going after militant groups inside Afghanistan unilaterally presents its own set of difficulties.
Chipping in
29 Mar, 2024

Chipping in

FEDERAL infrastructure development schemes are located in the provinces. Most such projects — for instance,...
Toxic emitters
29 Mar, 2024

Toxic emitters

IT is concerning to note that dozens of industries have been violating environmental laws in and around Islamabad....
Judiciary’s SOS
Updated 28 Mar, 2024

Judiciary’s SOS

The ball is now in CJP Isa’s court, and he will feel pressure to take action.
Data protection
28 Mar, 2024

Data protection

WHAT do we want? Data protection laws. When do we want them? Immediately. Without delay, if we are to prevent ...
Selling humans
28 Mar, 2024

Selling humans

HUMAN traders feed off economic distress; they peddle promises of a better life to the impoverished who, mired in...